University of Bath Develops Oral Delivery System for Injectable Protein Drugs
Key Insights
Researchers at the University of Bath have developed a breakthrough technology that enables oral delivery of protein-based drugs like growth hormone and monoclonal antibodies (search) that traditionally require injection.
The system uses a bacterial-derived carrier molecule that exploits natural intestinal transport mechanisms to deliver therapeutic proteins across the gut wall with 5-10% bioavailability.
The technology could transform treatment for chronic conditions requiring frequent injections, with human testing projected to begin within two years.
Researchers at the University of Bath have achieved a significant breakthrough that could revolutionize the way therapeutic proteins are administered, potentially eliminating the discomfort and inconvenience of injections for millions of patients worldwide. The innovative technology enables the oral delivery of protein-based drugs, such as hormones, antibodies, and peptides, which traditionally require injection due to their vulnerability to degradation in the digestive tract.
Novel Bacterial Transport Mechanism
The system, developed under the guidance of Professor Randy Mrsny from the Department of Life Sciences at the University of Bath, takes inspiration from the gut microbiome—specifically, bacteria that naturally manipulate host epithelial cells to transit substances across the intestinal lining. By conjugating therapeutic proteins to a non-toxic carrier molecule derived from cholera-associated bacteria, the researchers successfully exploit a highly specific receptor-mediated pathway.
"Whilst it's not the first system to replace injections, ours is the first platform to work safely and consistently, delivering the drug at effective doses and using a well understood pathway," Professor Mrsny said.
The carrier binds to receptors on intestinal epithelial cells (search) and triggers a transport process known as transcytosis, which ferries the drug intact across the gut wall without compromising the protective epithelial barrier. The design of the carrier molecule is derived from a domain of the cholix toxin, with the human Fc CH2 domain (search) modifying this pathway to enhance transcytosis efficiency without pathogenic effects.
Promising Preclinical Results
Animal studies have been pivotal in demonstrating the efficacy of this platform. In rat models, the researchers showed that proteins linked to the bacterial carrier could be absorbed into systemic circulation after oral administration. The system achieves a bioavailability of 5-10%, which, while modest, is sufficient to meet commercial viability standards.
Crucially, the pathway utilized does not induce epithelial damage or inflammation—common pitfalls in prior attempts—reducing risks and side effects associated with drug absorption enhancement strategies. "Unlike previous systems, our method doesn't damage the epithelium and can generically transport a large range of medications, including hormones and cancer (search) treatments that can currently only be injected," Professor Mrsny added.
Clinical Translation Timeline
These promising preclinical results have already attracted interest from pharmaceutical companies eager to optimize the technology further and pursue clinical trials. The timeline for human testing is projected within two years, signaling a rapid transition from bench to bedside. Initial human testing could begin within two years, pending further optimization with pharmaceutical partners.
Professor Mrsny emphasizes that the mechanistic insight underlying this approach derives directly from human intestinal biology, lending confidence to its translational potential. "This pathway is well understood and has been derived from events in the human intestine, so we know it will work in patients," he said.
Broad Therapeutic Applications
The use of a well-characterized receptor and transcytosis route means the delivery mechanism can be generalized across various therapeutic proteins. This versatility could transform treatments for a broad spectrum of diseases that currently rely on injections, including growth hormone deficiencies (search), immunotherapies for cancer (search), and cutting-edge metabolic drugs like Wegovy and Ozempic.
Proteins, especially therapeutic ones like human growth hormone or monoclonal antibodies (search), cannot be given orally in their current form because they are broken down by gastric acids and enzymes in the stomach and intestines. This intrinsic limitation has confined many lifesaving treatments to injectable formats, posing challenges such as pain, risk of infection, and patient non-compliance due to needle aversion or the inconvenience of self-administration.
Patient Impact and Healthcare Benefits
One of the transformative impacts of this system lies in improving patient experience and compliance. Eliminating needles would alleviate anxiety and discomfort, simplify treatment regimens, and reduce healthcare costs associated with injections, such as professional administration and the management of injection site infections. This is especially critical for pediatric patients requiring daily injectable growth hormones and individuals managing chronic illnesses over long periods.
Moreover, the implications extend beyond patient comfort. Oral delivery could improve drug stability, storage, and distribution logistics by removing the need for syringes or refrigeration-dependent injection devices. This could enhance access to life-saving treatments in resource-limited settings or remote areas where medical infrastructure and trained personnel are scarce.
Research Foundation
This advancement is anchored in rigorous experimental research, published in the Journal of Controlled Release, with significant support from industry leaders such as Novo Nordisk. The foundational work represents a blend of microbiology, protein engineering, pharmacology, and clinical science, showcasing the interdisciplinary nature of modern therapeutic innovation.
As the research progresses toward human applications, collaboration with pharmaceutical partners will be essential for formulation development, dosage optimization, and regulatory approvals. The compatibility of this delivery system with existing protein therapeutics could accelerate its integration into the pharmaceutical landscape, potentially sparking a paradigm shift in how injectable drugs are formulated, prescribed, and administered globally.